Water Street’s partnership with Bioclinica began in 2013 when we invested in CCBR-SYNARC. One year later, we facilitated a transformational merger between CCBR-SYNARC and Bioclinica that elevated the company to a premier global provider of specialty outsourced clinical trial services. Bioclinica completed six more strategic acquisitions that strengthened and broadened its capabilities across every major phase of clinical development. During the 3.5 years of our partnership, Bioclinica doubled in size and expanded its customer to more than 400 corporations, including the top 100 pharmaceutical companies and the top ten contract research organizations. Today, Bioclinica into one of the world’s leading providers of specialty clinical trial solutions. In 2016, a global firm acquired Bioclinica.
John Hubbard, Ph.D., FCP
President & Chief Executive OfficerWork with us
John Hubbard is a leader in the clinical services and biopharmaceutical R&D industries, with over three decades of experience including executive-level positions at Pfizer, ICON, Parexel and Hoechst Marion Roussel Pharmaceuticals. Prior to joining BioClinica, he was senior vice president and worldwide head of development operations for Pfizer, where he directed and oversaw clinical trial operations and management of more than 450 clinical projects. John was also a founding member of the board of directors of Transcelerate Biopharma, Inc. Previously, he was group president, Clinical Research Services at ICON Clinical Research. He is also a board member of Agile Therapeutics and the Association of Clinical Research Organizations (ACRO), and an advisory board member and fundraising vice-chair for the Children’s Brain Tumor Foundation. John received a bachelor’s degree in biopsychology from the University of Santa Clara and a doctorate from the University of Tennessee. He was an NIH postdoctoral fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center. John is an active member of the Society of Clinical Pharmacology and Therapeutics, a board certified diplomate in Applied Pharmacology and was elected as a Fellow of the American College of Clinical Pharmacology.